Business
Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
TORONTO, June 18 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI), a company developing products for t...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\nTORONTO, June 18 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI), a company\ndeveloping products for the treatment of sepsis, today announced that findings\ndemonstrating the Toraymyxin(TM) cartridge, a blood purification device that\nabsorbs endotoxin from the bloodstream, when added to conventional therapy,\nsignificantly improved hemodynamics and organ dysfunction and reduced 28-day\nmortality in patients with severe sepsis and septic shock. The article\nentitled "Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock:\nThe EUPHAS Randomized Controlled Trial," was published in the Journal of the\nAmerican Medical Association (JAMA). Spectral has exclusive rights to\nToraymyxin(TM) in the United States and plans to initiate a trial in the U.S.\nin the latter half of 2009.\n\n\n"The degree of reduction in mortality demonstrated by Toraymyxin(TM) in\nthe EUPHAS trial is an unprecedented result for sepsis therapies and indicates\nthat this product has the potential to fulfill an unmet need for the\napproximately 100,000 patients that develop severe sepsis or septic shock in\nthe U.S. each year," said Dr. Paul Walker, President and CEO of Spectral\nDiagnostics. "Our Endotoxin Activity Assay (EAA(TM)) has the ability to\nidentify patients who could benefit from this therapy and monitor its effect.\nTogether, this diagnostic and therapeutic have the potential to provide a more\neffective treatment for patients with severe sepsis and septic shock caused by\nendotoxemia."\n\n\nThe objective of this study was to determine whether Toraymyxin(TM), when\nadded to conventional medical therapy, improves clinical outcomes and\nmortality compared with conventional therapy alone, in a targeted patient\npopulation with severe sepsis and/or septic shock associated with\nintra-abdominal infections.\n\n\n- 28 day mortality was 32% (11/34 patients) in the Toraymyxin(TM) group\n and 53% (16/30 patients) in the conventional therapy group.\n- Mean Arterial Pressure (MAP) increased (76 to 84 mm Hg;\n P (equal sign) 0.001) in the Toraymyxin(TM) group but not in the\n conventional therapy group (MAP, 74 to 77 mm Hg; P (equal sign)\n 0.37).\n- Vasopressor requirement decreased (inotropic score, 29.9 to 6.8; P\n (less than) 0.001) at 72 hours in the Toraymyxin(TM) group but not in\n the conventional therapy group...